CHI-902 for Treatment of Social Anxiety Disorder

Status Withdrawn

Clinical Trial Summary

No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA) and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.

Clinical Trial Description

This study will evaluate efficacy, therapeutic effects, tolerability and safety of CBD oil in adults with SAD through a randomized placebo-controlled study design and will evaluate effects of CHI-902 on peripheral endocannabinoids (AEA and 2-AG). This study will be the first randomized, double-blind placebo-controlled trial conducted with CHI-902 in adults with SAD.

The study is designed to:

- Evaluate the efficacy of CHI-902 versus placebo in adults with SAD.

- Evaluate the tolerability and safety versus placebo of CHI-902 in adults with SAD.

- Explore the effects of CHI-902 versus placebo on different biomarkers in subjects with SAD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04086342
Study type	Interventional
Source	Canopy Health Innovations
Contact
Status	Withdrawn
Phase	Phase 2
Start date	January 24, 2020
Completion date	January 26, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06274112` - Using TMS to Understand Neural Processes of Social Motivation	N/A
Completed	`NCT02554929` - Treatment of Social Anxiety Disorder and Selective Mutism	N/A
Completed	`NCT00684541` - Interpretation Modification Program for Social Phobia	N/A
Completed	`NCT00684320` - Attention Disengagement Training for Social Phobia	N/A
Completed	`NCT03247075` - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT	N/A
Completed	`NCT02811458` - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders	N/A
Withdrawn	`NCT04622930` - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)	N/A
Active, not recruiting	`NCT05018312` - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety	N/A
Active, not recruiting	`NCT05124639` - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders	N/A
Completed	`NCT05858294` - The Safety, Acceptability and Efficacy of Alena	N/A
Active, not recruiting	`NCT05600114` - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Not yet recruiting	`NCT02924610` - Brief Intervention to Reduce Fear	Phase 4
Active, not recruiting	`NCT02592564` - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder	N/A
Recruiting	`NCT02305537` - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment	N/A
Terminated	`NCT03764644` - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders	N/A
Unknown status	`NCT01712321` - Study of Vilazodone to Treat Social Anxiety Disorder	N/A
Completed	`NCT01320800` - CBT for Social Anxiety Disorder Delivered by School Counselors	Phase 2
Completed	`NCT00485888` - Flushing in Social Anxiety Disorder on Cipralex	Phase 2
Completed	`NCT00773162` - Flushing in Social Anxiety Disorder on Seroquel	Phase 3